Sir Isaac Newton, sepsis, SIRS, and CARS

Critical Care Medicine

Volumn 24, Issue 7, 1996, Pages 1125-1126

  Bone, Roger C ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

critical illness; immune suppression; inflammation; interleukins; monoclonal antibodies; sepsis; systemic inflammatory response syndrome; tumor necrosis factor

Indexed keywords

COLONY STIMULATING FACTOR; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 13; INTERLEUKIN 4; MONOCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

ENDOTOXEMIA; GRAM NEGATIVE INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; MODEL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SEPSIS;

APOPTOSIS; CARDIOVASCULAR SYSTEM; HOMEOSTASIS; HUMANS; IMMUNE SYSTEM; INFLAMMATION; MODELS, THEORETICAL; SEPSIS;

EID: 0029903114     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199607000-00010     Document Type: Review

References (31)

1. Newton I: Philosophiae Naturalis Principia Mathematica. London, 1687
2. Bone RC: Gram-positive organisms and sepsis. Arch Intern Med 1994; 154: 26-34
3. American College of Chest Physicians/ Society of Critical Care Medicine Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and multiple organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-874
4. Bone RC: The pathogenesis of sepsis. Ann Intern Med 1991; 115:457-469
5. Matsushima K, Oppenheim JJ: Novel inflammatory cytokines inducible by IL-1 and TNF. Cytokine 1989; 1:2-13
6. Oppenheim JJ, Zachariae COC, Mukaida N, et al: Properties of the novel proinflammatory supergene "integrin" cytokine family. Annu Rev Immunol 1991; 9:617-647
7. Greenman RI, Schein RM, Martin MA, et al: A controlled clinical trial of E5 murine monoclonal antibody to endotoxin in the treatment of Gram-negative sepsis. JAMA 1991; 266:1097-1102
8. Ziegler EJ, Fisher CJ, Sprung CL, et al: Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 1991; 324:429-136
9. Abraham E, Wunderink R, Silverman H, et al: Efficacy and safety of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis syndrome. JAMA 1995; 273:934-941
10. Paper presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1994. Cited in Freeman BD, Natanson C: Clinical trials in sepsis and septic shock in 1994 and 1995. Curr Opin Crit Care 1995; 1:349-357
11. Paper presented at the Fifth Vienna Shock Forum, Vienna, 1995. Cited in Freeman BD, Natanson C: Clinical trials in sepsis and septic shock in 1994 and 1995. Curr Opin Crit Care 1995; 1: 349-357
12. Paper presented at the Third International Congress of the Immune Consequences of Trauma, Shock and Sepsis: Mechanisms and Therapeutic Approaches, Munich, 1995. Cited in Freeman BD, Natanson C: Clinical trials in sepsis and septic shock in 1994 and 1995. Curr Opin Crit Care 1995; 1:349-357
13. Fisher CJ, Dhainaut J-FA, Opal SM, et al: Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized, double-blind, placebo-controlled trial. JAMA 1994; 271: 1836-1844
14. Dhainaut J-FA, Tenaillon A, Le Tulzo Y, et al: Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 1994; 22:1720-1728
15. Dhainaut J-F, Tenaillon A, Hemmer M, et al: Confirming phase III clinical trial to study the efficacy of a PAF antagonist, BN 52021, in reducing mortality of patients with severe Gram-negative sepsis. Abstr. Am J Respir Crit Care Med 1995; 151:A447
16. Dinarello CA, Gelfand JA, Wolff SM: Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993; 269:1829-1835
17. Platzer C, Meisel CH, Vogt K, et al: Up-regulation of monocytic IL-10 by tumor necrosis factor-α and cAMP elevating drugs. Int Immunol 1995; 7:517-523
18. Doughty L, Patrene K, Boggs S, et al: Suppression of native IL-10 production by constitutive expression of viral IL-10 (vIL-10) or soluble TNF receptor p75 (sTNFR) in mice. Abstr. Crit Care Med 1996; 24(Suppl):A32
19. Doughty L, Kaplan S, Carcillo J: The IL-10 response in pediatric sepsis and organ failure. Abstr. Crit Care Med 1996; 24(Suppl):A32
20. Abraham E: Physiologic stress and cellular ischemia: Relationship to immunosuppression and susceptibility to infection. Crit Care Med 1991; 19:613-618
21. De Waal Malefyt R, Haanen J, Spits H, et al: Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174:915-924
22. Browder W, Williams D, Pretus H, et al: Beneficial effect of enhanced macrophage function in the trauma patient. Ann Surg 1990; 211:605-612
23. Hamilton G, Hofbauer S, Hamilton B: Endotoxin, TNF-α, interleukin-6 and parameters of the cellular immune system in patients with intraabdominal sepsis. Scand J Infect Dis 1992; 24: 361-368
24. Cheadle WG, Hershman MJ, Wellhausen SR, et al: Role of monocytic HLA-DR expression following trauma in predicting clinical outcome. In: Immune Consequences of Trauma, Shock, and Sepsis. Faist E, Ninnemann J, Green D (Eds). Berlin, Heidelberg, New York, Springer-Verlag, 1989, pp 199-122
25. Gibbons RA, Martinez OM, Lim RC, et al: Reduction in HLA-DR, HLA-DQ, and HLA-DP expression by Leu-M3+ cells from the peripheral blood of patients with thermal injury. Injury 1989; 19: 263-266
26. Wakefield CH, Carey PD, Foulds S, et al: Changes in major histocompatibility complex class II expression in monocytes and T cells of patients developing infection after surgery. Br J Surg 1993; 80: 205-209
27. Pinsky MR, Vincent J-L, Deviere J, et al: Serum cytokine levels in human septic shock. Chest 1993; 103:565-575
28. Fisher CJ Jr, Opal SM, Dhainaut J-F, et al: Influence on an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993; 21:318-327
29. Dofferhoff ASM, Vom VJJ, de Vries-Hospers HG, et al: Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans. Crit Care Med 1992; 20: 185-192
30. Leser H-G, Gross V, Scheibenbogen C, et al: Elevation of serum interleukin-6 concentration precedes acute-phase response and reflects severity in acute pancreatitis. Gastroenterology 1991; 101:782-785
31. Goldie AS, Fearon KCH, Ross JA, et al: Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA 1995; 274: 172-177